JP2025514287A5 - - Google Patents

Info

Publication number
JP2025514287A5
JP2025514287A5 JP2024563535A JP2024563535A JP2025514287A5 JP 2025514287 A5 JP2025514287 A5 JP 2025514287A5 JP 2024563535 A JP2024563535 A JP 2024563535A JP 2024563535 A JP2024563535 A JP 2024563535A JP 2025514287 A5 JP2025514287 A5 JP 2025514287A5
Authority
JP
Japan
Prior art keywords
cancer
seq
amino acid
acid sequence
antibody according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514287A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/066283 external-priority patent/WO2023212632A2/en
Publication of JP2025514287A publication Critical patent/JP2025514287A/ja
Publication of JP2025514287A5 publication Critical patent/JP2025514287A5/ja
Pending legal-status Critical Current

Links

JP2024563535A 2022-04-27 2023-04-27 抗ヌクレオフォスミン1抗体と抗体の抱合体の併用治療 Pending JP2025514287A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR20220100349 2022-04-27
GR20220100349 2022-04-27
PCT/US2023/066283 WO2023212632A2 (en) 2022-04-27 2023-04-27 Anti-nucleophosmin 1 antibody and antibody conjugate combination therapies

Publications (2)

Publication Number Publication Date
JP2025514287A JP2025514287A (ja) 2025-05-02
JP2025514287A5 true JP2025514287A5 (enExample) 2026-05-11

Family

ID=88519854

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563535A Pending JP2025514287A (ja) 2022-04-27 2023-04-27 抗ヌクレオフォスミン1抗体と抗体の抱合体の併用治療

Country Status (5)

Country Link
US (1) US20250325717A1 (enExample)
EP (1) EP4514857A2 (enExample)
JP (1) JP2025514287A (enExample)
CN (1) CN119677779A (enExample)
WO (1) WO2023212632A2 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11896619B2 (en) * 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer

Similar Documents

Publication Publication Date Title
Ricart et al. Technology insight: cytotoxic drug immunoconjugates for cancer therapy
Wu et al. Arming antibodies: prospects and challenges for immunoconjugates
US11718684B2 (en) Antibody binding specifically to MUC1 and use thereof
Sapra et al. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes
Allen Ligand-targeted therapeutics in anticancer therapy
Weiner et al. New approaches to antibody therapy
Smaglo et al. The development of immunoconjugates for targeted cancer therapy
US8309094B2 (en) Antibody-drug conjugates
RU2427590C2 (ru) Анти-mn антитела и способы их применения
CN113423735B (zh) 抗-紧密连接蛋白抗体及其用途
Damle Tumour-targeted chemotherapy with immunoconjugates of calicheamicin
CN113784987B (zh) 靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
RU2006105339A (ru) Rg1 антитела и их применение
KR920702692A (ko) 인체 암종과 반응성인 신규 항체
HRP20150806T1 (hr) Protutijela anti-cd22, njihovi imunokonjugati kao i njihove uporabe
CA2996205A1 (en) Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
CA2374398A1 (en) Immunoconjugates having high binding affinity
Zong et al. A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer
JP2024525624A5 (enExample)
Kitson et al. Antibody-drug conjugates (ADCs)–biotherapeutic bullets
JP2023546493A5 (enExample)
Tivadar et al. Monoclonal antibody targeting sialyl-di-Lewisa–containing internalizing and noninternalizing glycoproteins with cancer immunotherapy development potential
Lambert Antibody-maytansinoid conjugates: a new strategy for the treatment of cancer
Prabhu et al. Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology
JP2025514288A5 (enExample)